DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Tesis de maestría (MasterThesis)
Epigenetic factors in microglial cell modulation and testing of therapeutic agents relevant to Alzheimer's disease
Trabajo fin de máster presentado en la Universidad de Barcelona, Dept. Neuroscience and Experimental Therapeutics, Master in Translational Medicine, el 3 de junio de 2022.--Calificación: 8,5, Alzheimer's disease (AD) is a major problem facing aging countries around the world. As a degenerative disease of the central nervous system, AD is generally considered to be associated with neuroinflammation and immune responses activated by microglia and astrocytes. mCRP as a trigger of AD neuropathology after the cerebrovascular injury can be used as a pro-inflammatory agent in the research phase. This research analyzes the epigenetic changes of mCRP-induced microglia and explores that new perspective against neuroinflammation in AD. We incubated BV2 microglia for 24 h and then with 50 or 100 ¿M mCRP and LPS as pro-inflammatory factors. TPPU is an inhibitor of the soluble epoxide hydrolase enzyme (sEH), the conjugates JM039 and SK003 which are dual agents that combined soluble epoxide hydrolase (sEHi) and acetylcholinesterase inhibitor activities, and resveratrol (RV) were added for protective assays. The expression levels of different cytokines were measured by ELISA, Western blot, and qPCR experiments. The results showed that mCRP activated the nitric oxide pathway, and increased nitric oxide release and iNOS gene expression, while RV blocked these effects. mCRP increased the release of TNF¿ into the medium and the expression of proinflammatory cytokines and chemokines. As anti-inflammatory and antioxidant polyphenolic compounds, RV can down-regulate the expression of COX2 and NOS2. JM039 and SK003 showed statistically significant downregulation in NO and TNF-¿ generation. Furthermore, mCRP modifies the epigenetic microglial phenotype, suggesting a dysregulated pattern. Ultimately, we demonstrate that mCRP directly activates the microglial inflammatory pathway and may contribute to AD triggering and progression. sEHi showed to be promising agents against microglia activation. However, in the experimental conditions tested, RV showed a higher therapeutic potential to combat neuroinflammation in AD., MCIN/AEI/10.13039/501100011033 (#PID2019-106285RB-C22)